<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439917</url>
  </required_header>
  <id_info>
    <org_study_id>17086</org_study_id>
    <secondary_id>17/EM/0441</secondary_id>
    <nct_id>NCT03439917</nct_id>
  </id_info>
  <brief_title>Effects of Carnitine Supplementation on Liver and Muscle</brief_title>
  <acronym>ECLIPSE</acronym>
  <official_title>Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves&#xD;
      metabolism in individuals who have a high concentration of fat within their liver.&#xD;
      Participants will be given either Carnitine or placebo, together with a meal replacement&#xD;
      milkshake twice daily for 6 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NAFLD occurs when too much fat accumulates in liver tissue. This can, over time, cause&#xD;
      inflammation and scarring of the liver, eventually leading to chronic liver disease and&#xD;
      cirrhosis. It is strongly associated with diabetes and obesity, both of which are endemic in&#xD;
      Western societies.&#xD;
&#xD;
      Carnitine enables cells in the body to use fat as a fuel, and recent studies have suggested&#xD;
      that carnitine supplementation may reduce liver triglyceride content. Muscle and liver are&#xD;
      the major sites in the body which coordinate glucose and fat metabolism. As well as assessing&#xD;
      the effect of carnitine supplementation on liver fat, its effect on metabolic processes&#xD;
      within these tissues will also be measured&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intrahepatic triglyceride (IHTG) content</measure>
    <time_frame>24 weeks</time_frame>
    <description>IHTG measured by proton magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>liver sensitivity to insulin</measure>
    <time_frame>24 weeks</time_frame>
    <description>suppression of glucose output from the liver during a 20 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body insulin sensitivity</measure>
    <time_frame>24 weeks</time_frame>
    <description>whole body glucose uptake during a 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle lipid content</measure>
    <time_frame>24 weeks</time_frame>
    <description>lipid content of the vastus lateralis muscle measured by proton magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle sensitivity to insulin</measure>
    <time_frame>24 weeks</time_frame>
    <description>Arterialised-venous vs. femoral venous difference in blood glucose concentration during the last hour of a 2 hour 50 mU.m-2.min-1 hyperinsulinaemic euglycaemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body composition</measure>
    <time_frame>24 weeks</time_frame>
    <description>Fat and lean tissue mass assessment by dual energy X-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver energy metabolism</measure>
    <time_frame>24 weeks</time_frame>
    <description>hepatic ATP flux assessed by 31-phosphorous magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-Alcoholic Fatty Liver Disease</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g L-carnitine tartrate consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2g Maltodextrin consumed with a meal replacement milkshake (Slimfast, UK) twice a day for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Carnitine tartrate</intervention_name>
    <description>2g L-Carnitine tartrate as a powder consumed twice a day</description>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Meal Replacement Drink</intervention_name>
    <description>325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day</description>
    <arm_group_label>Carnitine and Meal Replacement Drink</arm_group_label>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
    <other_name>Slimfast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day</description>
    <arm_group_label>Placebo and Meal Replacement Drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Elevated liver fat on screening abdominal ultrasound&#xD;
&#xD;
          -  Capable of providing informed consent&#xD;
&#xD;
          -  Non-vegetarian diet&#xD;
&#xD;
          -  BMI &lt;40 kg/m2&#xD;
&#xD;
          -  Weekly ethanol consumption &lt;21 units/week&#xD;
&#xD;
          -  Negative non-invasive liver screen, including Hepatitis B and C serology, liver&#xD;
             autoantibodies, transferrin saturation, Î±1-antitrypsin levels.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of cardiovascular disease&#xD;
&#xD;
          -  Known diabetes mellitus&#xD;
&#xD;
          -  Known psychiatric comorbidity&#xD;
&#xD;
          -  Chronic kidney disease&#xD;
&#xD;
          -  Surgery within 6 months prior to start of study&#xD;
&#xD;
          -  Exposure to drugs known to influence hepatic steatosis (including steroids, statins,&#xD;
             omega-3-fatty acids)&#xD;
&#xD;
          -  Current smokers&#xD;
&#xD;
          -  Contraindications to magnetic resonance scanning, including implanted ferrous material&#xD;
             (implantable pacemakers or defibrillators), metallic ocular foreign bodies,&#xD;
             ferromagnetic aneurysm clips or severe claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guru Aithal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David Greenfield Human Physiology Unit</name>
      <address>
        <city>Nottingham</city>
        <state>Notts</state>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

